Roche's $7.1B bet on Roivant drug; AD­Cs and oth­er #ES­MO23 dis­patch; High­lights from Alzheimer's con­fab; Q3 phar­ma dra­ma; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Be­tween earn­ings sea­son, con­fer­ences and a busy con­gres­sion­al sched­ule, there is tru­ly no bor­ing day here at End­points. This week, we bring you our full ES­MO and CTAD cov­er­age, key take­aways from Q3 re­sults, as well as the splashy Roche deal and a play-by-play look at how Bris­tol My­ers Squibb end­ed up buy­ing Mi­rati.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER